MASI Stock Slips Despite Q2 Earnings and Revenue Beat, Margins Expand

Core Insights - Masimo Corporation (MASI) reported adjusted earnings per share (EPS) of $1.33 for Q2 2025, reflecting a 46.2% year-over-year increase and surpassing the Zacks Consensus Estimate by 8.1% [1] - The company's revenues reached $370.9 million in Q2 2025, marking a 7.9% year-over-year growth and exceeding the Zacks Consensus Estimate by 0.6% [2] - Masimo's gross profit increased by 12.5% year-over-year to $233.3 million, with a gross margin expansion of 262 basis points to 62.9% [6] Revenue Breakdown - Revenue excluding related party revenues was $345.1 million, up 8.2% year-over-year, while related party revenues were $25.8 million, up 2.8% year-over-year [4] - Healthcare revenues totaled $370.3 million, reflecting a 7.7% increase on a reported basis and 7.4% at constant exchange rates [5] - Consumable and service revenues within the Healthcare segment grew by 8.4%, while capital equipment and other revenues declined by 2% year-over-year [5] Margin and Expense Analysis - Adjusted operating profit for Q2 was $64.5 million, a 53.9% increase from the previous year, with an adjusted operating margin expansion of 521 basis points to 17.4% [8] - Selling, general, and administrative expenses rose by 9.9% year-over-year to $138.9 million, while research and development expenses decreased by 23.5% to $29.9 million [8] Financial Position - At the end of Q2 2025, Masimo had cash and cash equivalents of $149.6 million, up from $130.8 million at the end of Q1 2025, and long-term debt decreased to $598.7 million from $636 million [9] - Cumulative net cash provided by operating activities from continuing operations was $99.5 million, compared to $106 million a year ago [9] Guidance and Outlook - Masimo has raised its revenue outlook for 2025 to a range of $1,505 million to $1,535 million, reflecting an 8-11% increase at constant exchange rates from 2024 [10] - Adjusted EPS for 2025 is now projected to be between $5.45 and $5.70, indicating a growth of 30-36% from 2024 figures [11] Overall Assessment - The company demonstrated strong performance in Q2 2025 with better-than-expected results, particularly in Healthcare revenues and margin expansion [12] - However, lower capital equipment and other revenues were noted as a downside [13]